Speaker
Dr. Dan
Appearances over time
1 episodes
Episodes
1
Podcasts
Quotes & moments
Dr. Dan used OpenAI Codex to autonomously implement a full ERP system for a friend; it ran for 7 hours and 25 minutes overnight and finished end-to-end tested.
An entrepreneur Dr. Dan met at Network School fired 18 people — 15 customer support staff replaced by AI, and remaining developers replaced by Claude Code.
An entrepreneur cloned a $34,000/year B2B SaaS product by transcribing the sales call and feeding it to Claude Code, which rebuilt the product using the same APIs.
Taking a drug from early research to market approval costs an average of $2.3 billion and takes a median of 15 years.
Natural GLP-1 has a half-life of only 30 minutes in the blood; drug engineers have extended this to enable weekly injections with sustained effect.
Ozempic unlocked mass market adoption by reducing injections from twice daily (liraglutide) to once weekly while doubling the therapeutic effect.
AI lab subscriptions are deliberately priced below cost (loss leaders) to gain market share, while API pricing carries actual margins.
Dr. Dan cited that a very small percentage — potentially less than 1% — of positive results in mouse studies actually transfer to humans.
Coding subscriptions from Anthropic and OpenAI are deliberately priced below cost to capture market share. APIs carry the actual margins. Cursor is doing the same thing — just burning SpaceX's money instead of Microsoft's.
Cursor fine-tunes Chinese models, has no frontier AI, and its IDE is just a VS Code fork. The only real assets are user data and brand awareness — and Elon is burning SpaceX money to buy both. Dan gives seven to eight times more value per dollar from Codex than Claude Code.
B2B SaaS built on a glorified database is now a one-click clone. The industries with real staying power are those with physical assets, proprietary distribution, or deeply entrenched systems of record. Every other SaaS product will be commoditized like a cheap IKEA chair.
Dan gave Codex a detailed plan for a full ERP system and went to sleep. Seven hours and 25 minutes later, it was done — end-to-end tested, click-through verified. Claude Code can't do this. We are entering the era of fast fashion software.
Ozempic triggered a revolution by cutting injections from twice daily to once weekly. Retatrutide adds a third receptor key — GLP-1, GIP, and glucagon — delivering 28.3% body weight loss in Phase 3 trials. Think of each generation as a Pokemon evolution, and we're not close to the final form.
SpaceX is targeting $1.75 trillion at IPO — the largest in history. Dan calls it irrational hype driven by a master storyteller. Ben sees a monopoly in space launch, GPU-in-orbit economics, and a coming Taiwan-to-Texas chip migration. Rik bets retail FOMO sends it to $3–5T before the lock-up cliff.
Dan had dismissed Anthropic as marketing over substance. Then Andrej Karpathy — an OpenAI founding member — joined as an R&D researcher. Dan's take: Karpathy must know something the rest of us don't. One hire flipped the entire bull case.
One entrepreneur attended a $34,000/year B2B SaaS demo, transcribed the call, fed it to Claude Code, and had a working clone by morning. The product used the same public APIs. This is now the template — your sales pitch is your product spec.
OpenAI is giving $2M in credits to every YC startup — roughly $400M total. The real play: startups use those tokens to onboard users, burning through the credits and locking into OpenAI's ecosystem. When the credits run out, they keep paying. Sam gets a hand in every promising YC company.
In Shenzhen, Dan visited a company that manufactures factories — selling robotic arms and production lines to BYD, CATL, and global brands like KUKA. The twist: they OEM everything and forbid photos, because their customers don't want anyone to know who actually builds their equipment.
Developing a drug costs $2.3 billion over 15 years. You get 8 years to recoup it before generics hit. Meanwhile, US compounding pharmacies exploit a loophole to sell unbranded Ozempic for $50 instead of $1,500. It's the AI subscription pricing model applied to pharmaceuticals.
Peptides like BPC-157 and TB-500 are popular at biohacking retreats, but nearly all the evidence comes from animal studies. Less than 1% of mouse findings transfer to humans. Most peptide users are running an uncontrolled personal experiment with anecdotal backing.
A university lecturer Dan met in China casually mentioned her two side hustles — one of which is a factory with 40 employees exporting biological lacquer coatings. In China, 'side hustle' means real physical production. It completely reframes the Western obsession with digital micro-businesses.
Analysis
What they talk about
- Technology 46%
- Business 36%
- Health & Fitness 9%
- Society & Culture 9%
Connections
Shows they appear on and people they share episodes with. Drag to explore.
